EUCTR2018-004451-20-DE进行中（未招募）1 期
A multicenter, open label, single-arm pilot study to evaluate the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Each potential subject must satisfy all of the following criteria to be enrolled in the study:
- •1.Male or female, aged 18 years or more at screening visit
- •2.given written consent to participate in the study
- •3.has moderate to severe PPP defined as a ppPPPASI = 12 at baseline (week 0) with or without concomitant plaque-type psoriasis
- •4.a candidate for systemic treatment defined as having PPP inadequately controlled by topical treatment and/or phototherapy and/or previous sys-temic therapy
- •5.has chronic disease of PPP of 6 months calculated from date at which first symptoms were reported by subject to date of screening visit
- •6.Agree not to receive a live virus or live bacterial vaccination during the study, or within 3 months after the last administration of study drug
- •7.Agree not to receive a BCG vaccination during the study, or within 12 months after the last administration of study drug
- •8.Subjects with the ability to follow study instructions and likely to attend and complete all required visits
- •Reproduction-related inclusion criteria
- •Contraceptive (birth control) use by men or women should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies.
- •Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with local regulations regarding the use of contraceptive methods for subjects in clinical studies.
- •9.Before first administration of study drug, a woman must be
- •a. Not of childbearing potential
- •b. Of childbearing potential and practicing a highly effective method of contraception (failure rate of <1% per year when used consistently and correctly) and agrees to remain on a highly effective method method while receiving study treatment and until 12 weeks after last dose - the end of relevant systemic exposure. Examples of highly effective methods of contraception are located in section 9.4.
- •10.A woman of childbearing potential must have a negative urine preg-nancy test at screening and agree to urine pregnancy testing before re-ceiving injections and at safety follow-up.
- •11.A woman must agree not to donate eggs (ova, oocytes) for the pur-poses of assisted reproduction during the study and for a period of 12 weeks after receiving the last administration of guselkumab.
- •12.A male subject must wear a condom when engaging in any activity that allows for passage of ejaculate to another person.
- •13.A male subject must agree not to donate sperm for the purpose of reproduction during the study and for a minimum 12 weeks after receiving the last dose of study treatment.
- •TB-related inclusion criteria:
- •14. It is the responsibility of the investigator to verify the adequacy of previous anti-TB treatment and provide appropriate documentation.
- •a.Have no history of latent or active TB before screening
- •b.Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination.
- •c.Have had no recent close contact with a person with active TB or, if there has been such contact, will be referred to a physician specializing in TB
- •to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB before the first administration of study drug.
- •d.Within 2 months before the first administration of study drug, have a negative QuantiFERON®-TB Gold test result, or have a newly identified positive QuantiFERON-TB Gold test result in which active TB has been ruled out a
排除标准
- •General Exclusion Criteria:
- •1.Subject without legal capacity or is unable to understand the nature, scope, significance and consequences of this clinical trial
- •2.Simultaneously participation in another clinical trial or participation in any clinical trial involving administration of an investigational medicinal product within 4 weeks or 5 pharmacokinetic/pharmacodynamics half-lives (which-ever is longer)prior to participation in present clinical trial
- •3.Subjects with a physical or psychiatric condition which at the investigator’s discretion may put the subject at risk, may confound the trial results, or may interfere with the subject’s participation in this clinical trial
- •4.Known or persistent abuse of medication, drugs or alcohol
- •Indication specific exclusion criteria:
- •5. Known history of hypersensitivity to the investigational drug or to drugs with a similar chemical structure or to any components of guselkumab
- •6.Evidence of skin conditions (eg eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis.
- •7.Ultraviolet B (UVB) therapy, topical steroids, topical calcineurin inhibitors, topical Vitamin A or D analog preparations, or anthralin within 14 days of baseline.
- •Exceptions: low potency corticosteroids will be allowed as therapy for the face, groin, axillae in accordance with the manufacturers suggested usage dose.
- •8.Psoralen plus ultraviolet A radiation (PUVA), ciclosporin, acitretin, ale-facept (AmeviveTM), anakinra (KineretTM), systemic corticosteroids, methotrexate, fumaric acids, apremilast or any other systemic anti-psoriasis therapy within 28 days of baseline
- •9.antipsoriatic biologic therapy with TNF-a blockers or IL-17 blockers within 3 months and/or ustekinumab within 4 months
- •10.Prior treatment with guselkumab or other IL23-blockers
- •11.Receipt of ANY live (attenuated) vaccine within 3 months prior to baseline (week 0), and BCG vaccination within 12 months of screening.
- •12.Significant concurrent medical conditions at the time of screening, includ-ing:
- •a. Risk factors for renal toxicity (renal inflammation)
- •b. Severe hepatic dysfunction
- •c. Unstable angina pectoris
- •d. Uncompensated congestive heart failure
- •e. Severe pulmonary disease requiring hospitalization or supple-mental oxygen therapy
- •f. Immunodeficiency disorders: primary or secondary
- •g.Previous test positive for Human immunodeficiency virus (HIV, test result may not be older than 8 weeks at screening date)
- •h. Previous tests positive for hepatitis B virus (HBV) infection or tests seropositive for antibodies to hepatitis C virus (HCV), unless the patient has 2 negative HCV RNA test results 6 months apart after completing antiviral treatment and prior to baseline and has a third negative HCV RNA test result at baseline (test results may not be older than 8 weeks at screening date).
- •i. history of active granulomatous infection, including histoplasmosis or coccidioidomycosis, before screening. Refer to inclusion criterion 15 and 16 for information regarding eligibility with a history of latent TB
- •j. Uncontrolled Insulin-dependent diabetes mellitus
- •k. Currently has a malignancy or has a history of malignancy within 5 years before screening (with the exception of a nonmelanoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study drug administration or cervical carcinoma in situ that has been
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to demonstrate the significant improvement of Psoriasis Palmoplantaris Pustulosis in moderate to severe chronic palmoplantar pustulosis patients receiving Apremilast therapy.EUCTR2016-005122-11-DEProf. Dr. Kristian Reich20
招募中
Unknown
Transcatheter Arterial Micro-Embolization (TAME) using Nexsphere-F in Patients with Chronic Pain in Elbow or WristDiseases of the musculoskeletal system and connective tissueKCT0009270Konkuk University Medical Center38
招募中
1 期
ate-onset sepsis in term and pre-term neonates and infants up to 3 months of ageate-onset sepsis (LOS) in term and pre-term neonates andinfants up to 3 months of age.MedDRA version: 20.1Level: LLTClassification code 10053598Term: Late onset neonatal sepsisSystem Organ Class: 100000004862EUCTR2022-001837-35-LTBasilea Pharmaceutica International Ltd, Allschwil15
进行中（未招募）
1 期
ate-onset sepsis in term and pre-term neonates and infants up to 3 months of ageate-onset sepsis (LOS) in term and pre-term neonates andinfants up to 3 months of age.MedDRA version: 20.1Level: LLTClassification code 10053598Term: Late onset neonatal sepsisSystem Organ Class: 100000004862EUCTR2022-001837-35-PLBasilea Pharmaceutica International Ltd, Allschwil15
进行中（未招募）
1 期
ate-onset sepsis in term and pre-term neonates and infants up to 3 months of ageate-onset sepsis (LOS) in term and pre-term neonates andinfants up to 3 months of age.MedDRA version: 20.1Level: LLTClassification code 10053598Term: Late onset neonatal sepsisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2022-001837-35-SKBasilea Pharmaceutica International Ltd, Allschwil8